| 0.0761 -0.001 (-1.81%) | 04-18 15:06 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.16 | 1-year : | 0.23 |
| Resists | First : | 0.14 | Second : | 0.2 |
| Pivot price | 0.07  |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.07 |
| MA(100) : | 0.19 |
MA(250) : | 0.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.8 |
D(3) : | 50.2 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 1.26 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCEL ] has closed above bottom band by 39.2%. Bollinger Bands are 89.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.07 - 0.08 | 0.08 - 0.08 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Wed, 17 Apr 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS ... - The Malaysian Reserve
Wed, 17 Jan 2024
Gold Moves Lower; Phunware Shares Plummet - DatChat (NASDAQ:DATS), Atreca (OTC:BCEL) - Benzinga
Thu, 11 Jan 2024
Sera Prognostics, Atreca spike after Baker Bros stakes (NASDAQ:SERA) - Seeking Alpha
Thu, 11 Jan 2024
US Stocks Higher; Inflation Rate Increases To 3.4% In December - 180 Life Sciences (NASDAQ:ATNF), Atreca - Benzinga
Thu, 11 Jan 2024
Why Is Atreca (BCEL) Stock Up 85% Today? - InvestorPlace
Tue, 26 Dec 2023
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 24.4 (%) |
| Shares Short | 273 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.3 % |
| Return on Equity (ttm) | -182.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|